Drug intelligence / Profile preview

ThisCART22 cells

Development stage: Phase 1
Lead developer: Fundamenta Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

ThisCART22 cells is an investigational allogeneic chimeric antigen receptor T-cell (CAR-T) therapy developed by Fundamenta Therapeutics. It is designed to target the CD22 antigen, a transmembrane glycoprotein expressed on the surface of mature B cells and most B-cell malignancies. Unlike traditional autologous CAR-T therapies that use a patient's own cells, ThisCART22 is derived from healthy donors using a proprietary non-gene-editing approach. The therapy is currently being evaluated in Phase 1 clinical trials for the treatment of relapsed and/or refractory CD22-positive B-cell malignancies, including non-Hodgkin's B-cell lymphoma (r/r B-NHL).

Other names: Allogeneic CAR-T targeting CD22

Targets

CD22 (Cluster of Differentiation 22)

Beyond the preview

Go deeper on ThisCART22 cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ThisCART22 cells.